

Average Tumor Area of IL-12 Treated Mice with B16F10 Melanomas
Tumor area (mm2)
500
400
300
200
100
0
0
5
10
15
20
25
30
Days post inoculation
IP - 100ng
ID - 100ng
SC - 100ng
ID - PBS control

FIG. 1



Mortality Rate of C57BL Mice with B16F10 Melanomas After IL-12 Treatment
Animals remaining
Days post cellular inoculation
IP 100ng
ID 100ng
SC 100ng
ID PBS control
Neg Control
0
2
4
6
8
10
0
5
10
15
20
25
30

FIG. 2



MELANOMA#3 Percent CD49b cells in DLN over time
CD49b day14
CD49b day24
Percent cells in DLN
14
12
10
8
6
4
2
0
NEG CNTL-DLN
PBS-DLN
SC-DLN
ID-DLN
IP-DLN
Conditions

FIG. 3



Lung Levels of RSV-Specific Antibody after ID and IM Delivery
Nanograms of Antibody 50µg Lung Tissue
16
14
12
10
8
6
4
2
0
18% increase in bioavailability by ID delivery
IM
ID
3 hour
24 hour
1 week
2 week
3 week
4 week
Time

FIG. 4



Synagis Mab detected in lungs
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
ug/mL sy
1hour
3hour
5hour
Group (by time)
25ul
50ul
100ul

FIG. 5



+ Short term therapeutic conc.
- Longer term prophylactic conc.
[Synagis]
1-wk
?
+ Short term therapeutic conc.
+ Longer term prophylactic conc.
[Synagis]
1-wk
IN
IM
Cumul

FIG. 6



1 hour
Treatment Conc.
(6 µg/mL)
ng synagis / mL lung tissue lys
10000
1000
100
10
1
100% IM
15% IM/85% IM
naive
1 week
Prophylactic
Conc.
ng Synagis / mL lu
1000
100
10
1
100% IM
15% IM/85% IM
naive

FIG. 7



10^{-5} RSV stock dilution + 6 µg / mL Synagis
10^{-5} RSV stock dilution

FIG. 8

FIG. 9





FIG. 10






FIG. 11